Pharmaceuticals

Ranking by Total Asset (million Rp)

No. Company

Ranking by Shareholders' Equity (million Rp)

2005

2004

Change

1 Kalbe Farma Tbk

4,728,369

4,231,054

11.8%

2 Tempo Scan Pacific Tbk

2,345,760

2,141,419

3 Kimia Farma Tbk

1,177,603

4 Darya-Varia Laboratoria Tbk

No. Company

2005

2004

Change

1 Kalbe Farma Tbk

2,389,006

1,598,650

49.4%

9.5%

2 Tempo Scan Pacific Tbk

1,793,257

1,686,446

6.3%

1,173,438

0.4%

3 Kimia Farma Tbk

844,220

814,584

3.6%

550,629

431,174

27.7%

4 Darya-Varia Laboratoria Tbk

309,604

319,027

-3.0%

5 Indofarma Tbk

518,824

523,923

-1.0%

5 Indofarma Tbk

265,245

255,665

3.7%

6 Merck Tbk

218,034

200,466

8.8%

6 Merck Tbk

180,361

154,021

17.1%

7 Bristol-Myers Squibb Indonesia Tbk

7 Bristol-Myers Squibb Indonesia Tbk

101,245

126,809

-20.2%

63,471

62,143

2.1%

1,038

1,902

-45.4%

165,022

193,719

-14.8%

8 Pyridam Farma Tbk

76,551

70,430

8.7%

9 Schering Plough Indonesia Tbk

74,023

58,504

26.5%

Ranking by Total Liabilities (million Rp)

No. Company
1 Kalbe Farma Tbk

2005

8 Pyridam Farma Tbk

9 Schering Plough Indonesia Tbk

Ranking by Net Profit/Loss (million Rp)

2004

Change

1,821,584

2,284,131

-20.3%

2 Tempo Scan Pacific Tbk

472,473

379,832

3 Kimia Farma Tbk

333,382

358,855

4 Indofarma Tbk

253,578

5 Darya-Varia Laboratoria Tbk

160,025

No. Company

2005

2004

Change

1 Kalbe Farma Tbk

653,329

450,698

24.4%

2 Tempo Scan Pacific Tbk

296,825

323,093

45.0%
-8.1%

-7.1%

3 Darya-Varia Laboratoria Tbk

71,576

49,811

43.7%

268,258

-5.5%

4 Merck Tbk

57,700

57,239

0.8%

112,147

42.7%

5 Kimia Farma Tbk

52,827

77,755

-32.1%
32.5%

6 Schering Plough Indonesia Tbk

72,985

56,601

28.9%

6 Indofarma Tbk

9,595

7,239

7 Bristol-Myers Squibb Indonesia Tbk

63,777

66,910

-4.7%

7 Pyridam Farma Tbk

1,328

1,432

-7.3%

8 Merck Tbk

37,657

46,429

-18.9%

884

40,352

-97.8%

9 Pyridam Farma Tbk

13,080

8,287

57.8%

8 Bristol-Myers Squibb Indonesia Tbk

9 Schering Plough Indonesia Tbk

(864)

(332)

-160.2%